Business Context and Reporting Period
This Form 8-K is a Current Report filed by Cara Therapeutics, Inc. (not Tvardi Therapeutics, Inc., which is the target of a proposed acquisition) on December 30, 2024. The filing primarily addresses a corporate restructuring event and provides updates regarding a proposed acquisition transaction.
Key Financial Metrics
This filing is a current report regarding corporate governance and capital structure changes. It does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity metrics. The filing text does not provide a clear value for any financial performance indicators.
Material Changes
- Reverse Stock Split: The Company effected a one-for-twelve (1-for-12) reverse stock split of its outstanding common stock, effective at 5:00 p.m. Eastern Time on December 30, 2024.
- Authorized Shares Reduction: The total number of authorized shares of common stock was reduced from 200,000,000 to 16,666,667.
- Trading Adjustments: Common stock began trading on a split-adjusted basis on The Nasdaq Capital Market on December 31, 2024, under the new CUSIP number 140755 208.
- Equity Plan Adjustments: Proportionate adjustments were made to the per-share exercise price and number of shares issuable for all outstanding stock options and equity compensation plans.
- Fractional Shares: No fractional shares were issued; stockholders entitled to fractional shares received cash payments in lieu thereof.
Guidance, Outlook, and Material Events
- Proposed Acquisition: The filing relates to a proposed acquisition transaction between Cara Therapeutics, Inc. and Tvardi Therapeutics, Inc.
- Regulatory Filings: A registration statement on Form S-4 containing a proxy statement and prospectus has been filed with the SEC regarding the proposed transaction.
- Investor Action: The Company urges investors to read the Form S-4 and related materials carefully before making voting or investment decisions.
- Participants in Solicitation: Directors and executive officers of both Cara Therapeutics and Tvardi Therapeutics are deemed participants in the proxy solicitation.
Key Facts for Investor Verification
- Verify the new CUSIP number (140755 208) for post-split trading.
- Review the Form S-4 registration statement for details on the proposed acquisition of Tvardi Therapeutics, Inc.
- Confirm the impact of the 1-for-12 reverse split on individual holdings and outstanding options.
- Check for any cash payments received in lieu of fractional shares.
- Monitor the status of the proposed transaction and any required stockholder votes.